Treatment Sequencing After Failure of the First Biologic in Cost-Effectiveness Models of Psoriasis: A Systematic Review of Published Models and Clinical Practice Guidelines

Cost-effectiveness models of first-line biologics for moderate to severe plaque psoriasis either do not include subsequent treatment regimens or include only some of the regimens recommended in current treatment guidelines. Results may be sensitive to assumptions about treatment sequencing and the choice and efficacy of subsequent treatment regimens. </AbstractSection> Copyright The Author(s) 2014

MoreLess

Year of publication:	2014
Authors:	Mauskopf, Josephine ; Samuel, Miny ; McBride, Doreen ; Mallya, Usha ; Feldman, Steven
Published in:	PharmacoEconomics. - Springer, ISSN 1170-7690. - Vol. 32.2014, 4, p. 395-409
Publisher:	Springer

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10011001547